Cargando…

Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis

This study aimed to compare the efficacy of allogeneic stem cell transplantation (allo-SCT) versus autologous SCT (auto-SCT) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Medline, CENTRAL, and EMBASE databases through December 31, 2019 were searched. The primary endpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianhong, Duan, Xiaohui, Yang, Lijie, Liu, Xiangxiang, Hao, Caixia, Dong, Hongjuan, Gu, Hongtao, Tang, Hailong, Dong, Baoxia, Zhang, Tao, Gao, Guangxun, Liang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784574/
https://www.ncbi.nlm.nih.gov/pubmed/33238731
http://dx.doi.org/10.1177/0963689720975397
_version_ 1783632317547282432
author Wang, Jianhong
Duan, Xiaohui
Yang, Lijie
Liu, Xiangxiang
Hao, Caixia
Dong, Hongjuan
Gu, Hongtao
Tang, Hailong
Dong, Baoxia
Zhang, Tao
Gao, Guangxun
Liang, Rong
author_facet Wang, Jianhong
Duan, Xiaohui
Yang, Lijie
Liu, Xiangxiang
Hao, Caixia
Dong, Hongjuan
Gu, Hongtao
Tang, Hailong
Dong, Baoxia
Zhang, Tao
Gao, Guangxun
Liang, Rong
author_sort Wang, Jianhong
collection PubMed
description This study aimed to compare the efficacy of allogeneic stem cell transplantation (allo-SCT) versus autologous SCT (auto-SCT) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Medline, CENTRAL, and EMBASE databases through December 31, 2019 were searched. The primary endpoints were overall survival (OS) and progression-free survival (PFS) rates. The secondary outcomes include transplant-related mortality (TRM), event-free survival, relapse/or progression, and nonrelapse mortality (NRM). The 18 retrospective studies enrolled 8,058 B-NHL patients (allo-SCT = 1,204; auto-SCT = 6,854). The OS was significantly higher in patients receiving auto-SCT than allo-SCT (pooled odds ratio [OR]: 1.69, 95% confidence interval [CI]: 1.29 to 2.22, P < 0.001), but no significant difference was found in PFS (pooled OR: 0.98, 95% CI: 0.69 to 1.38, P = 0.891). Auto-SCT patients also had lower TRM and NRM (TRM: OR = 0.23, P < 0.001; NRM: OR = 0.16, P < 0.001), but higher relapse or progression rate (OR = 2.37, P < 0.001) than allo-SCT patients. Subgroup analysis performed for different grades and subtypes of B-NHL showed higher OS in auto-SCT patients with high-grade B-NHL and diffused large B-cell lymphoma (DLBCL). There was, nevertheless, higher PFS in allo-SCT patients with low-grade B-NHL and follicular lymphoma (FL), and lower PFS in allo-SCT patients with DLBCL than their auto-SCT counterparts. In conclusion, the meta-analysis demonstrated that relapsed or refractory B-NHL patients who received auto-SCT have improved OS than those treated with allo-SCT, especially among those with DLBCL, but lower PFS among those with FL. However, the study is limited by a lack of randomized trials, patients’ heterogeneity, and possible selection bias.
format Online
Article
Text
id pubmed-7784574
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77845742021-01-14 Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis Wang, Jianhong Duan, Xiaohui Yang, Lijie Liu, Xiangxiang Hao, Caixia Dong, Hongjuan Gu, Hongtao Tang, Hailong Dong, Baoxia Zhang, Tao Gao, Guangxun Liang, Rong Cell Transplant Original Article This study aimed to compare the efficacy of allogeneic stem cell transplantation (allo-SCT) versus autologous SCT (auto-SCT) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Medline, CENTRAL, and EMBASE databases through December 31, 2019 were searched. The primary endpoints were overall survival (OS) and progression-free survival (PFS) rates. The secondary outcomes include transplant-related mortality (TRM), event-free survival, relapse/or progression, and nonrelapse mortality (NRM). The 18 retrospective studies enrolled 8,058 B-NHL patients (allo-SCT = 1,204; auto-SCT = 6,854). The OS was significantly higher in patients receiving auto-SCT than allo-SCT (pooled odds ratio [OR]: 1.69, 95% confidence interval [CI]: 1.29 to 2.22, P < 0.001), but no significant difference was found in PFS (pooled OR: 0.98, 95% CI: 0.69 to 1.38, P = 0.891). Auto-SCT patients also had lower TRM and NRM (TRM: OR = 0.23, P < 0.001; NRM: OR = 0.16, P < 0.001), but higher relapse or progression rate (OR = 2.37, P < 0.001) than allo-SCT patients. Subgroup analysis performed for different grades and subtypes of B-NHL showed higher OS in auto-SCT patients with high-grade B-NHL and diffused large B-cell lymphoma (DLBCL). There was, nevertheless, higher PFS in allo-SCT patients with low-grade B-NHL and follicular lymphoma (FL), and lower PFS in allo-SCT patients with DLBCL than their auto-SCT counterparts. In conclusion, the meta-analysis demonstrated that relapsed or refractory B-NHL patients who received auto-SCT have improved OS than those treated with allo-SCT, especially among those with DLBCL, but lower PFS among those with FL. However, the study is limited by a lack of randomized trials, patients’ heterogeneity, and possible selection bias. SAGE Publications 2020-11-26 /pmc/articles/PMC7784574/ /pubmed/33238731 http://dx.doi.org/10.1177/0963689720975397 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Wang, Jianhong
Duan, Xiaohui
Yang, Lijie
Liu, Xiangxiang
Hao, Caixia
Dong, Hongjuan
Gu, Hongtao
Tang, Hailong
Dong, Baoxia
Zhang, Tao
Gao, Guangxun
Liang, Rong
Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
title Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
title_full Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
title_fullStr Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
title_full_unstemmed Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
title_short Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
title_sort comparison of survival between autologous and allogeneic stem cell transplantation in patients with relapsed or refractory b-cell non-hodgkin lymphoma: a meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784574/
https://www.ncbi.nlm.nih.gov/pubmed/33238731
http://dx.doi.org/10.1177/0963689720975397
work_keys_str_mv AT wangjianhong comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT duanxiaohui comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT yanglijie comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT liuxiangxiang comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT haocaixia comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT donghongjuan comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT guhongtao comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT tanghailong comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT dongbaoxia comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT zhangtao comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT gaoguangxun comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis
AT liangrong comparisonofsurvivalbetweenautologousandallogeneicstemcelltransplantationinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaametaanalysis